News

In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside the weak year-on-year comparisons, Novavax beat analyst expectations for both revenue and earnings and highlighted progress on high-profile partnerships, including Sanofi and Pfizer, while also filing an US$82.47 million...

Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expense guidance and outlines potential Sanofi milestones ahead.

Novavax (NASDAQ:NVAX) reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in its Sanofi partnership, expanding use of its Matrix-M adjuvant platform and continued cost reductions. Revenue declined from $239 million a year earlier, primarily

Novavax secures key partnerships and raises 2026 outlook while advancing its adjuvant platform in infectious disease and oncology.

Novavax raised its full-year 2026 adjusted total revenue outlook to $235–$275 million from $230–$270 million.

ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam.

Novavax Inc. (NASDAQ:NVAX) reported second-quarter results that came in ahead of Wall Street expectations, while also increasing its full-year revenue outlook as its partnership with Sanofi continued to move forward.

Novavax (NVAX) delivered earnings and revenue surprises of +11.11% and +13.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Here is how Novavax (NVAX) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

Vaccine biotechnology company Novavax (NASDAQ:NVAX) announced better-than-expected revenue in Q2 CY2026, but sales fell by 76.3% year on year to $56.7 million. Its GAAP loss of $0.32 per share was 16.6% above analysts’ consensus estimates.

HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.

Why Novavax’s Licensing Pivot and Cyclospora Focus Matter Now Novavax (NVAX) is in the spotlight after shifting away from direct COVID-19 vaccine sales toward licensing its Matrix-M adjuvant, while investors also weigh Cyclospora outbreak headlines and the upcoming second-quarter earnings release. See our latest analysis for Novavax. At a share price of $7.66, Novavax has seen a 3.37% 1 day share price return and a 4.36% 7 day share price return, although the 30 day share price return is down...

Novavax stock has staged a modest recovery in the past year, yet the longer record is still heavily negative and current market multiples screen as expensive for many investors looking at valuation. With the company scoring in the middle of the range on broader checks, the picture is more nuanced than a simple cheap or expensive label. Over the past 5 years, Novavax has delivered a decline of about 96.8%, which keeps longer term holders deeply under water despite shorter term...

Novavax is scheduled to release its second-quarter 2026 financial results before the U.S. market opens on Thursday.

In the most recent trading session, Novavax (NVAX) closed at $7.37, indicating a -1.6% shift from the previous trading day.

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Novavax (NVAX) reached $7.88 at the closing of the latest trading day, reflecting a -4.02% change compared to its last close.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Harmony Biosciences posts preliminary Q2 2026 Wakix revenues of about $261M, up 30% year over year, while reaffirming full-year guidance despite a CFO transition.

In the latest trading session, Novavax (NVAX) closed at $8.42, marking a -5.5% move from the previous day.

Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.

Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.

Novavax (NVAX) has been removed from several Russell growth and small cap benchmarks, a shift that can influence index fund ownership and prompt investors to reassess how the stock fits in their portfolios. See our latest analysis for Novavax. The index removals come after a mixed run for Novavax, with the share price at $9.40 and a 30 day share price return of 8.42%, a 90 day share price return of 15.76%, and a year to date share price return of 31.84%. This is set against a 1 year total...

Novavax (NasdaqGS:NVAX) has been removed from multiple major Russell growth indices. The changes follow the latest Russell index review and rebalancing cycle. Exclusion affects its presence in certain growth focused benchmarks tracked by passive funds. Novavax focuses on protein based vaccines, including its Covid 19 product and other pipeline candidates. Index changes arrive as vaccine makers continue to adjust to post pandemic demand patterns, shifting procurement models, and evolving...

Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.

Novavax (NVAX) concluded the recent trading session at $9.35, signifying a -1.16% move from its prior day's close.

ATAI completes dosing in the phase IIb Elumina study of VLS-01 for treatment-resistant depression, with top-line efficacy and safety data due in fourth-quarter 2026.

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.